Longitudinal Symptom Analysis of COVID-19 Survivors and Post-COVID Syndrome Patients.

Publication date: May 29, 2025

Background/Objectives: The present study aimed to analyze changes in symptom intensity during the recovery period of COVID-19 survivors and patients with post-COVID syndrome. Methods: Initially, we described a new remote patient monitoring system to track the intensity of specific symptoms in individuals’ home environments. Remote patient monitoring (RPM) was implemented over 15 days in a cohort of 133 individuals aged 20 to 78 years, divided into four groups: mild (MG, n = 40), Hospital Discharge Without Invasive Mechanical Ventilation (WIMV, n = 40), Hospital Discharge With Invasive Mechanical Ventilation (IMV, n = 13), and reinfected (RG, n = 40). Results: The most prevalent symptoms reported across all groups, based on average intensity, were shortness of breath, fatigue, cough, headache, and body pain. The WIMV group exhibited the highest average intensities in six symptoms (p < 0. 01), while the IMV group reported the highest averages in four symptoms (p < 0. 05). Fatigue was the symptom with the highest overall intensity, followed by memory lapses. The hospitalized groups demonstrated the highest intensities and most persistent symptoms (p < 0. 05). Blood pressure was significantly higher in the MG group compared to the RG group (p < 0. 0001), although all values remained within the normal range. Conclusions: These results provide novel insights, revealing distinct differences in the symptom profiles among the studied groups. These findings hold significant implications for developing more personalized care strategies and informing future pandemic preparedness and response efforts.

Open Access PDF

Concepts Keywords
Biomedicines COVID-19
Cough fatigue
Covid post-COVID
Future remote patient monitoring
Home SARS-CoV-2

Semantics

Type Source Name
disease IDO symptom
disease MESH COVID-19
disease MESH Syndrome
disease MESH home environments
disease MESH shortness of breath
disease IDO blood
disease MESH Long Covid
drug DRUGBANK BIA
drug DRUGBANK Ribostamycin
drug DRUGBANK Coenzyme M
disease MESH Parasitic Diseases
disease MESH cough headache
disease MESH sore throat
disease MESH sequelae
drug DRUGBANK Trestolone
disease MESH community spread
disease IDO process
disease MESH infection
disease IDO history
drug DRUGBANK Oxygen
disease MESH reinfection
disease MESH hypertension
disease MESH comorbidity
drug DRUGBANK Azithromycin
drug DRUGBANK Hydroxychloroquine
drug DRUGBANK Ivermectin
disease MESH Overweight
disease MESH Obesity
disease MESH Severe obesity
disease MESH Diabetes mellitus
disease MESH Prediabetes
disease MESH Cardiomegaly
disease MESH Hypercholesterolemia
disease MESH COPD
disease MESH pulmonary emphysema
disease MESH chronic bronchitis
disease MESH Asthma
pathway KEGG Asthma
disease MESH Anxiety
disease MESH Depression

Original Article

(Visited 8 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *